DSM-5 Changes in Diagnostic Criteria of Sexual Dysfunctions

Tobia, Waguih William IsHak Gabriel

doi:10.4172/2161-038x.1000122

Cited by 42 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HSDD (once defined as an absence/deficiency of sexual interest/desire, leading to significant distress and interpersonal difficulties [3]) is now considered by the DSM-5 as a female sexual interest/arousal disorder, requiring any three of the following criteria for diagnosis: absent/decreased sexual interest, erotic thoughts/fantasies, excitement/pleasure, initiation of sexual activity (or responsiveness to partner's attempts to initiate it), sexual cue responses, and sensations during sexual activity [4].…”

Section: Introductionmentioning

confidence: 99%

Flibanserin: First Global Approval

Deeks

2015

Drugs

View full text Add to dashboard Cite

Flibanserin (Addyi™) is chemically described as a benzimidazole and is being developed by Sprout Pharmaceuticals for the treatment of hypoactive sexual desire disorder (HSDD). The drug has a high affinity for serotonin 5-HT1A and 5-HT2A receptors (5-HT1A agonist/5-HT2A antagonist) and is believed to treat HSDD by increasing levels of dopamine and noradrenaline and lowering levels of serotonin in the brain. Flibanserin has been approved in the USA for the treatment of premenopausal women with acquired, generalized HSDD. Earlier phase III development of the agent for HSDD in the EU and Canada had been discontinued by Boehringer Ingelheim, following regulatory feedback. Boehringer Ingelheim had also evaluated flibanserin for the treatment of depression but, due to displaying very mild antidepressant activity, its development in this indication was discontinued. This article summarizes the milestones in the development of flibanserin leading to its first approval for HSDD.

show abstract

Section: Introductionmentioning

confidence: 99%

Flibanserin: First Global Approval

Deeks

2015

Drugs

View full text Add to dashboard Cite

show abstract

“…For example, by asking Sarah what "de-sexualized" meant to her, it became clear that Sarah defined sex as penile-vaginal intercourse (Gershoni et al, 2008). Sarah elaborated by stating that her doctor diagnosed her with a sexual dysfunction, listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM) as Genitopelvic Pain and Penetration Disorder (Gabriel Tobia, 2013). This opened up a conversation about heteronormative definitions of sex and intimacy, and provided an opportunity to make visible discourses related to gender, sexuality, and mental health, where sexuality outside of intercourse is pathologized and psychiatrized.…”

Section: Introductionmentioning

confidence: 99%

Politicized Narrative Therapy

Dumaresque¹,

Thornton²,

Glaser³

et al. 2018

cswr

View full text Add to dashboard Cite

Using a poly-vocal approach, this piece calls for the interruption and interrogation of narrative therapy’s colonial associations (White & Epston, 1990), and the cooption of narrative therapy by psychiatry under the guise of progressiveness (J. Poole, Personal Communication, January 31, 2017). We locate narrative therapy in the neoliberal geography of recovery and marketization, where social problems are coded as individual struggles, personal stories are used as mental health marketing material, and the burden of wellness enables psychiatric governance (Costa et al., 2012; Morrow, 2013; Poole, 2011). Drawing on Sefa Dei and Asgharzadeh’s (2001) anti-colonial discursive framework, critical race theory and its technique of counter-storytelling, Patricia Hill Collins’ (1990) Black feminist thought, and anti-sanist theorizing, we explore the possibility of reimagining narrative therapy for political ends. Throughout this piece, we draw on narrative techniques to move beyond an individual understanding of distress, connecting personal struggles to the broader social and political context. We do this by extending a political lens to the four steps taken in a mainstream narrative approach. We have chosen to use case studies informed by our own lived experiences in order to highlight the potential that we see in narrative work. This approach does not leave narrative therapy unchallenged and we understand that by remaining in a narrative framework housed in social work practice we cannot truly separate our approach from colonial care (Baskin, 2016; Lee & Ferrer, 2014). Rather, we hope to start a critical and transparent conversation that begins to explore the reconceptualization of narrative therapy for the purpose of deconstructing dominant discourses and making any colonial connections visible.

show abstract

“…In 2013, the American Psychiatric Association published the fifth edition of Diagnostic and Statistical Manual of Mental Disorders ( DSM ), with changes, simplifying the classification of sexual dysfunctions from four categories to three categories ( Figure 1 ). 9 – 11 The previous categories of female hypoactive desire disorder and female arousal dysfunction were combined into a single syndrome called sexual interest/arousal disorder. Also, the newly introduced syndrome termed “genitopelvic pain/penetration disorder” combines the formerly separate dyspareunia and vaginismus disorders.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, the dysfunction cannot be better explained by a nonsexual mental disorder or by severe relationship distress. 10 , 11 Although it is important to have a simple and clear diagnostic classification system, the recent classification change can make interpretation and comparison of past studies to present studies more complex.…”

Section: Introductionmentioning

confidence: 99%

Has testosterone passed the test in premenopausal women with low libido? A systematic review

Reed¹,

Nemer²,

Carr³

2016

IJWH

View full text Add to dashboard Cite

BackgroundThere are limited evaluation and treatment options for low libido in premenopausal women. This review sought to evaluate the available evidence supporting the evaluation of testosterone serum levels and testosterone treatment of premenopausal women with low libido.MethodsMEDLINE, PubMed, and ClinicalTrials.gov were searched for articles that referenced the evaluation of testosterone serum level and/or testosterone treatment on premenopausal women with low libido from 1995 to 2015. Additional references were obtained from the reference sections of other papers and from peer review. Studies that included only postmenopausal women were excluded. A total of 13 studies were reviewed in detail. Nine studies examined the relationship between testosterone serum levels and sexuality, an additional three studies examined the effect of testosterone treatment on premenopausal women with low libido, and one study examined both the topics.ResultsSix of the ten testosterone serum evaluation studies failed to show a significant association between testosterone serum level and libido. Only one out of four studies examining testosterone treatment in premenopausal women was able to show any clear improvement in libido; however, the effect was limited to only the intermediate dose of testosterone, with the low and high doses of testosterone not producing any effect.ConclusionThe currently available evidence does not support testosterone serum evaluation or treatment in premenopausal women with low libido. Hence, further studies are warranted.

show abstract

DSM-5 Changes in Diagnostic Criteria of Sexual Dysfunctions

Cited by 42 publications

References 16 publications

Flibanserin: First Global Approval

Flibanserin: First Global Approval

Politicized Narrative Therapy

Has testosterone passed the test in premenopausal women with low libido? A systematic review

Contact Info

Product

Resources

About